Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7896011 | 0.78 | POLB (0.44) | GAAMGAMSIMGAM2LMNA | |
| SCHEMBL435620 | 0.78 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11765179 | 0.78 | GAA (0.52) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2982758 | 0.77 | CYP1A2 (0.47) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL15439128 | 0.77 | L3MBTL1 (0.39) | ALDH1A1CYP1A2TSHRPOLBCYP2D6 | |
| Hydrochloric Acid SCHEMBL6896809 | 0.76 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL7910864 | 0.76 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL8351379 | 0.76 | MGAM (0.44) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28602640 | 0.76 | LPAR3 (0.45) | GAAMGAMSIMGAM2 | |
| SCHEMBL639641 | 0.74 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3772130-B1 | ADDITIVE FOR NON-AQUEOUS ELECTROLYTE SOLUTIONS, NON-AQUEOUS ELECTROLYTE SOLUTION, AND ELECTRICITY STORAGE DEVICE | SUMITOMO SEIKA CHEMICALS (JP) | 2026-05-06 | — | — | EP | disclosed |
| US-12620622-B2 | Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same | DAIKIN INDUSTRIES, LTD. (JP) | 2026-05-05 | — | — | US | disclosed |
| US-20260058199-A1 | NON-AQUEOUS ELECTROLYTE FOR SECONDARY BATTERY, LITHIUM ION BATTERY, AND LITHIUM ION CAPACITOR | SUMITOMO SEIKA CHEMICALS (JP) | 2026-02-26 | — | — | US | disclosed |
| US-20250337021-A1 | ELECTRODE FOR LITHIUM ION BATTERIES, AND LITHIUM ION BATTERY | SUMITOMO SEIKA CHEMICALS (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20250323274-A1 | LITHIUM-ION BATTERY ELECTRODE AND LITHIUM-ION BATTERY | SUMITOMO SEIKA CHEMICALS (JP) | 2025-10-16 | — | — | US | disclosed |
| US-20250260063-A1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM-ION SECONDARY BATTERY | DAIKIN INDUSTRIES, LTD. (JP) | 2025-08-14 | — | — | US | disclosed |
| EP-3780232-B1 | ELECTROLYTIC SOLUTION, ELECTROCHEMICAL DEVICE, LITHIUM-ION SECONDARY BATTERY, AND MODULE | DAIKIN IND LTD (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20250174720-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12315885-B2 | Electrolytic solution, electrochemical device, lithium-ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-27 | — | — | US | disclosed |
| EP-4553940-A1 | SECONDARY BATTERY | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-14 | — | — | EP | disclosed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101622751-A | Nonaqueous electrolyte solution and nonaqueous electrolyte battery | MITSUBISHI CHEM CORP | 2010-01-06 | — | — | CN | disclosed |
| US-20090075979-A1 | CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | AXYS PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1474400-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)] -6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003068756-A1 | 2-[5-(5-CARBAMIMIDOYL-1H-HETEROARYL)]-6-HYDROXYBIPHENYL-3-YL DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-08-21 | — | — | WO | disclosed |
| US-5273549-A | Crosslinking agent containing at least two carboxyl groups and a phosphate group | SOCIETE FRANCAISE HOECHST (FR) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075979-A1 | CETP Inhibitors | CETP, APOB, MTTP | GAA 2519/4885MGAM 3936/4885SI 905/4885 |
| US-20250174720-A1 | ELECTROLYTE, ELECTROCHEMICAL DEVICE, LITHIUM ION SECONDARY BATTERY, AND MODULE | HCN2, HCN1, HCN3 | GAA 3690/4885MGAM 3705/4885SI 4172/4885 |
| US-20050245537-A1 | Use of compounds having ccr antagonism | CCR1, CCR3, CCR2 | GAA 3552/4885MGAM 3340/4885SI 1916/4885 |
| US-20260058199-A1 | NON-AQUEOUS ELECTROLYTE FOR SECONDARY BATTERY, LITHIUM ION BATTERY, AND LITHIUM ION CAPACITOR | KCNN2, KCNN1, SLC9A1 | GAA 1375/4885MGAM 2576/4885SI 4611/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | GAA 3552/4885MGAM 3340/4885SI 1916/4885 |
| US-20050203094-A1 | 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors | F7, HABP2, F13B | GAA 805/4885MGAM 2097/4885SI 1706/4885 |
| US-12620622-B2 | Compound including sulfur-containing heterocyclic cation and bis(oxolato)borate anion, electrolytic solution and electrochemical device including the same | ASH2L, OLA1, ODC1 | GAA 3344/4885MGAM 3291/4885SI 3686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.